Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer
Small Cell Lung Cancer
About this trial
This is an interventional treatment trial for Small Cell Lung Cancer focused on measuring Dinutuximab, Irinotecan, Topotecan
Eligibility Criteria
Inclusion Criteria:
- Have histologically or cytologically confirmed SCLC (undifferentiated small-cell carcinoma arising in or consistent with lung cancer origin).
- Documented relapse or disease progression during or after first-line platinum-based therapy (subjects refractory to initial platinum-based therapy are eligible).
- Have no curative therapy available.
- Have a life expectancy of at least 12 weeks.
- Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Have adequate bone marrow and hepatic function.
- Have calculated creatinine clearance (CrCL) ≥30 mL/minute or serum creatinine ≤1.5 times below the upper limit of normal.
- Women of reproductive potential must not be pregnant or breastfeeding and have a negative urine or serum pregnancy test obtained within 7 days prior to the first dose of study treatment.
- Subjects must agree to consistently use 2 forms of highly effective contraception/birth control between signing of the informed consent and 60 days after the last study drug administration.
Exclusion Criteria:
- Candidate for re-treatment with original platinum-based regimen as second-line therapy.
- Prior treatment with irinotecan, topotecan, or dinutuximab.
- Have active brain metastases. Subjects with brain metastases are allowed if they completed definitive brain therapy, are asymptomatic and radiologically stable, and if they are not currently receiving corticosteroids or radiation.
- Have mixed small cell and non-small cell histologic features.
- Have a previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta and Tis [carcinoma in situ]) or any previous cancer curatively treated <3 years ago.
- Have a history or current evidence of uncontrolled cardiovascular disease.
- Have not recovered from prior surgery, significant trauma, systemic anticancer therapy, radiation therapy or investigational therapy to Grade 1 or better toxicity prior to enrollment (Part 1) or randomization (Part 2).
- Have had organ allograft or hematopoietic transplantation.
- Known to be human immunodeficiency virus (HIV) positive.
- Have an active infection requiring treatment or one that is clinically serious in the Investigator's opinion.
- Have received a live vaccine within 6 months of enrollment (Part 1) or randomization (Part 2).
- Exposure to strong CYP3A4 and/or UGT1A1 inhibitors and strong CYP3A4 inducers within 14 days of enrollment (Part 1) or randomization (Part 2).
- Have any clinical condition that is considered unstable or might jeopardize the safety of the subject and/or influence the subject's compliance in the study.
Sites / Locations
- Alaska Clinical Research Center
- Cancer Treatment Centers of America - Western Regional Medical Center
- Innovative Clinical Research Institute
- Genesis Cancer Center
- USC Norris Comprehensive Cancer Center
- VA Palo Alto Health Care System
- Olive View - UCLA
- Innovative Clinical Research Institute
- Hartford Hospital
- Eastern Connecticut Hematology and Oncology Assoc
- Alpha Oncology Research LLC
- 21st Century Oncology
- Comprehensive Hematology Oncology
- Winship Cancer Institute, Emory University
- Northwest Georgia Oncology Centers, P.C.
- Baptist Health Floyd Cancer Center
- Physicians' Clinic of Iowa Hematology and Oncology
- Kentucky Cancer Clinic
- University of Kentucky
- 21st Century Oncology
- Cox Health Medical
- Billings Clinic Cancer Center
- St. Vincent Frontier Cancer Center
- The University of New Mexico Comprehensive Cancer Center
- UH Cleveland Medical Center
- Cancer Treatment Centers of America at Southwestern RMC
- Kaiser Permanente Northwest Center for Health Research CRSS
- Fox Chase Cancer Center Office of Clinical Research
- Cancer Treatment Centers of America at Eastern Regional Medical Center
- Charleston Oncology
- Spartanburg Medical Center/Gibbs Cancer Center and Research Institute
- Prairie Lakes Health Care
- Center for Biomedical Research
- Texas Health Physicians Group
- Plano Cancer Institute
- The University of Texas Health Science Center at Tyler, Office of Clinical Studies
- Vista Oncology (Shelton office)
- United Hospital Center
- Camden Clark Medical Center / Regional Cancer Center
- University of Wisoncsin - Carbone Cancer Ctr
- Mid North Coast Cancer Institute Coff Habour Health Campus
- Mater Misericordiae Limited and Mater Medical Research Institute Limited
- Royal Adelaide Hospital
- Ballarat Health Services
- Medical Oncology Department, Specialized Hospital for Active Treatment of Oncology Sveti Mina EOOD - Blagoevgrad
- Department of Medical Oncology, Complex Oncology Center - Burgas EOOD, Burgas
- Medical Oncology Department, Multiprofile Hospital for Active Treatment - Dobrich AD, Dobrich
- Medical Oncology Department, Multiprofile Hospital for Active Treatment - Dr. Tota Venkova AD, Gabrovo
- Medical Oncology Department, Multiprofile Hospital for Active Treatment - Uni Hospital OOD, Panagiurishte
- Clinic of Oncology, UMHAT Dr. Georgi Stranski - Pleven
- Clinic of Oncology, UMHAT Pulmed
- First Department of Medical Oncology, Gastroenterology and Pulmology, Complex Oncology Center - Plovdiv EOOD
- First Department for Medical Oncology, Multiprofile Hospital for Active Treatement Serdika EOOD, Sofia
- Medical Oncology Clinic, Multiprofile Hospital for Active Treatment (MHAT) for Female's Health - Nadezhda OOD, Sofia
- Medical Oncology Department, University Multiprofile Hospital for Active Treatment Sv. Ivan Rilski EAD, Sofia
- Clinic for Chemotherapy, Specialized Hospital for Active Treatment in Oncology EAD, Sofia
- Clinic of Oncology, UMHAT SofiaMed
- Clinic of Oncology, MHAT Sveta Marina
- Cross Cancer Institute - Clinical Trials Unit
- Horizon Health Network - The Moncton Hosoital
- Princess Margaret Cancer Centre
- Windsor Regional Hospital Cancer Program
- McGill University Health Center
- L'Institut Universitaire de Cardiologie et de pneumologie de Quebec
- Hopital Nord
- Institut Regional du Cancer de Montpellier
- Institut de Cancérologie de l'Ouest - Centre Paul Papin
- Clinique Victor Hugo
- URCOT : Unité de Recherche Commune en Oncologie Thoracique Service de pneumologie de l'hôpital de la Croix-Rousse
- URCOT : Unité de Recherche Commune en Oncologie Thoracique Service de pneumologie de l'hôpital de la Croix-Rousse
- Service de Pneumologie aiguë et Cancérologie Thoracique Centre hospitalier Lyon-Sud
- CHU Brest
- Centre François Baclesse
- CHI Créteil
- Institut Paoli-Calmettes, Service Dòncologie Médicale
- Institut de Cancérologie de l'Ouest - Centre René Gauducheau
- Centre Paul Strauss
- Nouvel Hôpital Civil de Strasbourg
- LTD High Technology Hospital Medcenter
- LTD ''Accad. F. Todua Medical Center-Research Institute of Clinical Medicine''
- High Technology Medical Center, University Clinic
- Institute of Clinical Oncology
- Multiprofile Clinic Consillium Medulla
- Princess Margaret Hospital
- Queen Elizabeth Hospital
- Queen Mary Hospital
- Hetenyi Geza Hospital
- Koranyi National Institute of Pulmonology - Horváth
- Koranyi National Institute of TBC and Pulmonology
- Korányi National Institute
- Semmelweis Egyetem AOK Pulmonologiai Klinika
- Veszprém Megyei Tüdőgyógyintézet
- Matrai Gyogyintezet
- Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház, Semmelweis Tagkórház, Tüdőgyógyászati Osztály
- Komarom-Esztergom Megyei Onkorm. Szent Borbala Korhaza
- Tudogyogyintezet Torokbalint
- Zala Megyei Szent Rafael Korhaz
- Sri Venkateshwara Hospitals
- KLES Dr Prabhakar Kore Hospital & MRC
- Jaslok Hospital & Research Center
- Deenanath Mangeshkar Hospital
- Grant Medical Foundation Ruby Hall Clinic
- Birla Cancer Centre, SMS Hospital
- Healthcare Global (HCG) Towers
- Bhagawan Mahaveer Cancer Hospital
- Dipartimento di Oncologia, ARNAS Garibaldi
- Istituto Nazionale dei Tumori
- Istituto Europeo di Oncologia (IEO), Milano
- Ospedale Santa Maria della Misericordia, Perugia
- Radiation Oncology, Campus Bio-Medico University
- Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena
- A.O.U. San Luigi Gonzaga, Orbassano (Torino)
- Kosin University Gospel Hospital
- Chungbuk National University Hospital
- Kyungpook National University Medical Center
- Kyungpook University Chilgok Hospital
- Keimyung University Dongsan Medical Centre
- Chungnam National University Hospital
- CHA Bundang Medical Center
- Seoul National University Bundang Hospital
- Pusan National University Yangsan Hospital
- Inha University Hospital
- Chonnam National University Hwasun Hospital
- Gachon Universtiy Gil Medical Center
- Korea University Anam Hospital
- Seoul National University Boramae Medical Center
- Ulsan University Hospital
- Wonju Severance Christian Hospital
- Hospital of Lithuanian University of Health Sciences (LSMU) Kauno Klinikos
- National Cancer Institute
- Vilnius University Hospital Santaros Klinikos
- Hospital Kuala Lumpur
- Department of Medicine, Faculty of Medicine
- Hospital Umum Sarawak
- National Cancer Institute
- Cebu Doctors University Hospital
- Davao Doctors Hospital
- Manila Doctors Hospital
- St. Luke's Medical Center - Quezon City
- St. Luke's Medical Centre
- Szpital Specjalistyczny w Prabutach Sp. z o.o
- Samodzielny Publiczny Zespół Gruźlicy i Chorób Płuc w Olsztynie
- Samodzielny Specjalistyczny ZespółZakładów Opieki Zdrowotnej im. dr. Teodora Dunina
- Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy
- Szpital Chorób Płuc im Św. Józefa w Pilchowicach
- Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeylandów
- Centrum Onkologii-Instytut im. Sklodowskiej-Curie
- Wojskowy Instytut Medyczny
- Centrum Terapii Wspolczesnej J.M. Jasnorzewska sp. komandytowo-akcyjna
- Oncopremium Team LTD
- Institute of Oncology Prof. Dr. I.Chiricuta Cluj-Napoca
- Medisprof LTD
- SC Oncolab LTD
- SC Oncology Center Sf. Nectarie LTD
- Emergency County Hospital Satu-Mare, Medical Oncology Clinic
- Emergency Hospital ,Sf. Ioan cel Nou'
- Oncocenter Oncology Clinic LTD
- State Budgetary Healthcare Institution of Arkhangelsk Region Arkhangelsk Clinical Oncology Dispensary
- State Budgetary Healthcare Institution of Sverdlovsk Region, Sverdlovsk Regional Oncology Dispensary
- Region Budgetary Healthcare Institution, Kursk Regional Clinical Oncology Dispensary of Healthcare Committee of Kursk Region
- Federal State Budgetary Institution, Natiоnal Medical Research Center of Oncology n.a. N.N. Blokhin of Ministry of Healthcare of the Russian Federation
- State Budgetary Healthcare Institution of Moscow, Moscow City Oncology Hospital #62 of Moscow Healthcare Department
- State Budgetary Healthcare Institution of Arkhangelsk region "Arkhangelsk Clinical Oncology Dispensary"
- State Budgetary Healthcare Institution of Novosibirsk Region, Сity Clinical Hospital #1
- State Budgetary Healthcare Institution of Novosibirsk Region, Novosibirsk Regional Oncology Dispensary
- Budgetary Healthcare Institution of Omsk Region, Clinical Oncology Dispensary
- State Budgetary Healthcare Institution, Orenburg Regional Clinical Oncology Dispensary
- Center of Palliative Care-Devita LLC
- State Budgetary Healthcare Institution, Leningrad Regional Clinical Hospital
- BioEq, LLC
- Federal State Budgetary Institution, Scientific Research Institute of Oncology n.a. Petrov
- State Budgetary Healthcare Institution, Saint-Petersburg Clinical Scientific Practical Center of Specialized Kinds of Medical Care (Oncological)
- Saint-Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary
- State Budgetary Healthcare Institution, Samara Regional Clinical Oncology Dispensary
- State Budgetary Healthcare Institution of Yaroslavl Region, Regional Oncology Hospital
- St. Jacob´s Hospital Bardejov - Department of Clinical Oncology
- Faculty Hospital Zilina
- Hospital General Universitario de Elche
- Hospital Universitario Marqués de Valdecilla
- CHU A Coruña
- Hospital Universitario Puerta de Hierro
- Complejo Hospitalario de Navarra
- Hospital General de Alicante
- Hospital Quirón Dexeus
- Hospital Universitari Vall d´Hebron
- Hospital Universitario Reina Sofia
- Instituto Catalán de Oncología (ICO) - Josep Trueta
- Hospital Universitario Lucus Augusti
- Hospital General Universitário Gregorio Marañón
- Hospital Universitario La Paz
- Hospital Universitario Madrid Norte Sanchinarro
- H. M. Puerta del Sur (H. Móstoles)
- Hospital Regional de Málaga (H. Carlos Haya)
- Complexo Hospitalario Universitario de Ourense (CHUO)
- Hospital Virgen de los Lirios Alcoy
- Corporació Sanitària Parc Taulí
- Hospital Universitario Virgen de Valme
- Hospital Universitario y Politécnico de La Fe
- Hospital Álvaro Cunqueiro
- Hospital Lozano Blesa
- E-Da Hospital
- E-Da Hospital
- Kaohsiung Chang Gung Memorial Hospital
- Chung Shan Medical University Hospital
- Chi Mei Hospital, Liouying
- Chang-Gung Memorial Hospital, Linkou
- King Chulalongkorn Memorial Hospital
- National Cancer Institute of Thailand
- Siriraj Hopsital
- Maharaj Nakorn Chiang Mai Hospital
- Srinagarind Hospital
- Naresuan University Hospital
- Songklanagarind Hospital
- Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council," Municipal Institution "Multifield Dnipropetrovsk City Hospital #4" of Dnipropetrovsk Regional Council, Department of Chemotherapy
- Municipal Nonprofit Institution "Cental Municipal Clinical Hospital" of Uzhgorod City Council, Municipal Oncology Centre
- Regional Communal Nonprofit Enterprise, Municipal Institution Chernivtsi Regional Clinical Oncology Dispensary, Surgery Department, State Higher Educational Establishment of Ukraine, Bukovinian State Medical University, Department of Onc and Radiology
- Communal Non-profit Enterprise "Kyiv City Clinical Oncology Center" of Executive body of Kyiv City Council, Kyiv City Clinical Oncology Center by Main Department of Health Protection Kyiv, Hospital of Day Stay for Oncology Patients
- Municipal Nonprofit Institution "Odessa Regional Oncology Dispensary" of Odessa Regional Council, Municipal Institution Odesa Regional Oncology Dispensary, Hospital of Day Stay (Unit of Dispensary-Polyclinic Department)
- Municipal Nonprofit Institution "Podilsky Regional Oncology Center" of Vinnytsa City Council, Podilsky Regional Oncology Сenter, Department of Chemotherapy
- Princess Alexandra Hospital
- Royal Marsden Hospital
- St James' Institute of Oncology
- St Bartholomew's Hospital
- Royal Free Hospital
- Guy's and St Thomas' NHS Foundation Trust
- Royal Marsden Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Active Comparator
Experimental
Active Comparator
Part 1: Dinutuximab + Irinotecan
Part 2: Irinotecan
Part 2: Dinutuximab + Irinotecan
Part 2: Topotecan
Dinutuximab (10 mg/m^2 IV) + Irinotecan (350 mg/m^2 IV) on Day 1 of every 21 days (q21d). Dinutuximab dose will be escalated in 2 mg/m^2 increments per cycle if maximal pain is <Grade 2 (and without opioids) and otherwise tolerated, up to a maximum dose of 17.5 mg/m^2 IV.
Irinotecan (350 mg/m^2 IV) on Day 1 of each q21d cycle.
Dinutuximab (16 mg/m^2 IV) + Irinotecan (350 mg/m^2 IV) on Day 1 of each q21d cycle. Dinutuximab dose will be escalated in 2 mg/m^2 increments per cycle if maximal pain is <Grade 2 (and without opioids) and otherwise tolerated, up to a maximum dose of 17.5 mg/m^2 IV.
Topotecan (1.5 mg/m^2 IV) on Days 1 to 5 of each q21d cycle.